Effects of Relacorilant on Pituitary Tumor Volume in Patients With Cushing Disease: Results From the Phase 3 GRACE Study

Summary

Relacorilant is in development for the treatment of endogenous hypercortisolism and has demonstrated improvements in hypertension, hyperglycemia, and other manifestations of cortisol excess in the phase 3 GRACE study
Efficacy was observed without reported cases of relacorilant-induced hypokalemia, adrenal insufficiency, vaginal bleeding associated with endometrial hypertrophy, or QT interval prolongation
In the open-label phase of GRACE, pituitary tumor volume decreased or remained unchanged following relacorilant treatment for 87% of patients with Cushing Disease
One patient with a macroadenoma had complete resolution with no visible residual tumor by magnetic resonance imaging after relacorilant treatment